Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides

Development of potent and broad-spectrum antivirals against SARS-CoV-2 remains one of top priorities, especially in the case of that current vaccines cannot effectively prevent viral transmission. We previously generated a group of fusion-inhibitory lipopeptides, with one formulation being evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yue, Zhu, Yuanmei, Yu, Yanying, Liu, Nian, Ju, Xiaohui, Ding, Qiang, He, Yuxian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977133/
https://www.ncbi.nlm.nih.gov/pubmed/36868315
http://dx.doi.org/10.1016/j.antiviral.2023.105571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977133/
https://www.ncbi.nlm.nih.gov/pubmed/36868315
http://dx.doi.org/10.1016/j.antiviral.2023.105571

Ejemplares similares